Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
Original Article
M. Greenhawt, S.B. Sindher, J. Wang, M. O’Sullivan, G.d. Toit, E.H. Kim, D. Albright, S. Anvari, N. Arends, P.D. Arkwright, P. Bégin, K. Blumchen, T. Bourrier, T. Brown-Whitehorn, H. Cassell, E.S. Chan, C.E. Ciaccio, A. Deschildre, A. Divaret-Chauveau, S.L. Dorris, M.J. Dorsey, T. Eiwegger, M. Erlewyn-Lajeunesse, D.M. Fleischer, L.S. Ford, M. Garcia-Lloret, L. Giovannini-Chami, J.O. Hourihane, N. Jay, S.M. Jones, L.A. Kerns, K.M. Kloepfer, S. Leonard, G. Lezmi, J.A. Lieberman, J. Lomas, M. Makhija, C. Parrish, J. Peake, K.P. Perrett, D. Petroni, W. Pfützner, J.A. Pongracic, P. Quinn, R.G. Robison, G. Sanders, L. Schneider, H.P. Sharma, J. Trujillo, P.J. Turner, K. Tuttle, J.E. Upton, P. Varshney, B.P. Vickery, C. Vogelberg, B. Wainstein, R.A. Wood, K.J. Bee, D.E. Campbell, T.D. Green, R. Rouissi, A. Peillon, H.T. Bahnson, T. Bois, H.A. Sampson, and A.W. Burks
N Engl J Med 2023;388:1755-1766
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation